NDATOPICALLOTION
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
4/8 — Partial
IMPEKLO (clobetasol propionate) by R-Pharm US is clinical pharmacology: the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. Approved for psoriasis, atopic dermatitis. First approved in 2020.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMPEKLO is a topical clobetasol propionate lotion, a potent Class I corticosteroid approved in 2020 for psoriasis and atopic dermatitis. It works by suppressing inflammatory and immune responses in the skin through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms. Clobetasol propionate can be absorbed systemically but shows transient and reversible HPA axis effects upon discontinuation.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30/100); team size and growth trajectory depend on R-Pharm US's dermatology portfolio investment.
Mechanism of Action
CLINICAL PHARMACOLOGY: The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical…
Worked on IMPEKLO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.